News

News

New hope for Niemann-Pick Disease Type C treatment as Bloomsbury Genetic Therapies receives Orphan Drug Designations

Learn More

News

The Times names UCL University of the Year 2024

Learn More

News

Phasecraft raises £13m, led by Playground Global, to become the first to reach practical quantum advantage

Learn More

News

UCL backed tumour-busting cancer therapy cleared for clinical trials

Learn More

News

Investor Q&A: Barny Cox

Learn More

News

Orchard Therapeutics presents additional positive data regarding MPS-IH

Learn More

News

UCLB spinout Orchard Therapeutics to be acquired by Kyowa Kirin for $477m

Learn More

News

Bramble Energy reveals world’s ‘lowest cost’ hydrogen fuel cell

Learn More

News

UCL partner Apollo Therapeutics receives $226.5m to translate medical research into treatments

Learn More

News

Treatment for infantile neuroaxonal dystrophy a step closer as Bloomsbury Genetic Therapies receives Orphan Drug Designations

Learn More

News

New Alzheimer’s hope as UCLB spinout AstronauTx closes $61m Series A financing

Learn More

News

Bloomsbury Genetic Therapies Receives Rare Pediatric Disease Designation from the U.S. FDA for BGT-INAD for the Treatment of Infantile Neuroaxonal Dystrophy (INAD) and Announces Upcoming Type B Pre-IND Meeting with the U.S. FDA

Learn More

News

Bloomsbury Genetic Therapies Receives Orphan Drug Designation from the U.S. FDA for BGT-OTCD for the Treatment of Ornithine Transcarbamylase Deficiency (OTCD)

Learn More

News

Quell Therapeutics signs a collaboration, exclusive option and license agreement with AstraZeneca

Learn More

Investments

Fast-charging battery startup Gaussion powers up with backing from BGF and UCL Technology Fund

Learn More

News

Hazy raises $9m to power synthetic data usage in enterprises

Learn More

Investments

Intrinsic Semiconductor Technologies Secures £7m Investment

Learn More

Insights

Investor Q&A: Leigh Brody

Learn More

Reach out

New hope for Niemann-Pick Disease Type C treatment as Bloomsbury Genetic Therapies receives Orphan Drug Designations

The Times names UCL University of the Year 2024

Phasecraft raises £13m, led by Playground Global, to become the first to reach practical quantum advantage

UCL backed tumour-busting cancer therapy cleared for clinical trials

Investor Q&A: Barny Cox

Orchard Therapeutics presents additional positive data regarding MPS-IH

UCLB spinout Orchard Therapeutics to be acquired by Kyowa Kirin for $477m

Bramble Energy reveals world’s ‘lowest cost’ hydrogen fuel cell

UCL partner Apollo Therapeutics receives $226.5m to translate medical research into treatments

Treatment for infantile neuroaxonal dystrophy a step closer as Bloomsbury Genetic Therapies receives Orphan Drug Designations

New Alzheimer’s hope as UCLB spinout AstronauTx closes $61m Series A financing

Bloomsbury Genetic Therapies Receives Rare Pediatric Disease Designation from the U.S. FDA for BGT-INAD for the Treatment of Infantile Neuroaxonal Dystrophy (INAD) and Announces Upcoming Type B Pre-IND Meeting with the U.S. FDA

Bloomsbury Genetic Therapies Receives Orphan Drug Designation from the U.S. FDA for BGT-OTCD for the Treatment of Ornithine Transcarbamylase Deficiency (OTCD)

Quell Therapeutics signs a collaboration, exclusive option and license agreement with AstraZeneca

Fast-charging battery startup Gaussion powers up with backing from BGF and UCL Technology Fund

Hazy raises $9m to power synthetic data usage in enterprises

Intrinsic Semiconductor Technologies Secures £7m Investment

Investor Q&A: Leigh Brody

News & Stories

Filter

Orchard Therapeutics presents additional positive data regarding MPS-IH

New hope for Niemann-Pick Disease Type C treatment as Bloomsbury Genetic Therapies receives Orphan Drug Designations

UCLB spinout Orchard Therapeutics to be acquired by Kyowa Kirin for $477m

Bramble Energy reveals world’s ‘lowest cost’ hydrogen fuel cell

Business Insider: Bramble named among the 23 startups inventing moonshot technology that are set to take off

Bloomsbury GTX presents new Preclinical Data on CNS Programs at the European Society of Gene & Cell Therapy (“ESGCT”) Congress 2022

The Times names UCL University of the Year 2024

UCL partner Apollo Therapeutics receives $226.5m to translate medical research into treatments

Phasecraft raises £13m, led by Playground Global, to become the first to reach practical quantum advantage

UCL backed tumour-busting cancer therapy cleared for clinical trials

Investor Q&A: Barny Cox

Treatment for infantile neuroaxonal dystrophy a step closer as Bloomsbury Genetic Therapies receives Orphan Drug Designations

New Alzheimer’s hope as UCLB spinout AstronauTx closes $61m Series A financing

Let’s Talk

Reach out

Related Content

New hope for Niemann-Pick Disease Type C treatment as Bloomsbury Genetic Therapies receives Orphan Drug Designations

The Times names UCL University of the Year 2024

Phasecraft raises £13m, led by Playground Global, to become the first to reach practical quantum advantage

UCL backed tumour-busting cancer therapy cleared for clinical trials

Investor Q&A: Barny Cox

Orchard Therapeutics presents additional positive data regarding MPS-IH

UCLB spinout Orchard Therapeutics to be acquired by Kyowa Kirin for $477m

Bramble Energy reveals world’s ‘lowest cost’ hydrogen fuel cell

UCL partner Apollo Therapeutics receives $226.5m to translate medical research into treatments

Treatment for infantile neuroaxonal dystrophy a step closer as Bloomsbury Genetic Therapies receives Orphan Drug Designations

New Alzheimer’s hope as UCLB spinout AstronauTx closes $61m Series A financing

Bloomsbury Genetic Therapies Receives Rare Pediatric Disease Designation from the U.S. FDA for BGT-INAD for the Treatment of Infantile Neuroaxonal Dystrophy (INAD) and Announces Upcoming Type B Pre-IND Meeting with the U.S. FDA

Bloomsbury Genetic Therapies Receives Orphan Drug Designation from the U.S. FDA for BGT-OTCD for the Treatment of Ornithine Transcarbamylase Deficiency (OTCD)

Quell Therapeutics signs a collaboration, exclusive option and license agreement with AstraZeneca

Fast-charging battery startup Gaussion powers up with backing from BGF and UCL Technology Fund

Hazy raises $9m to power synthetic data usage in enterprises

Intrinsic Semiconductor Technologies Secures £7m Investment

Investor Q&A: Leigh Brody

News & Stories

Filter

Orchard Therapeutics presents additional positive data regarding MPS-IH

New hope for Niemann-Pick Disease Type C treatment as Bloomsbury Genetic Therapies receives Orphan Drug Designations

UCLB spinout Orchard Therapeutics to be acquired by Kyowa Kirin for $477m

Bramble Energy reveals world’s ‘lowest cost’ hydrogen fuel cell

Business Insider: Bramble named among the 23 startups inventing moonshot technology that are set to take off

Bloomsbury GTX presents new Preclinical Data on CNS Programs at the European Society of Gene & Cell Therapy (“ESGCT”) Congress 2022

The Times names UCL University of the Year 2024

UCL partner Apollo Therapeutics receives $226.5m to translate medical research into treatments

Phasecraft raises £13m, led by Playground Global, to become the first to reach practical quantum advantage

UCL backed tumour-busting cancer therapy cleared for clinical trials

Investor Q&A: Barny Cox

Treatment for infantile neuroaxonal dystrophy a step closer as Bloomsbury Genetic Therapies receives Orphan Drug Designations

New Alzheimer’s hope as UCLB spinout AstronauTx closes $61m Series A financing

Let’s Talk